Safety, Tolerability and Pharmacokinetic/Pharmacodynamic Characteristics of LC350189

PHASE1CompletedINTERVENTIONAL
Enrollment

129

Participants

Timeline

Start Date

June 30, 2011

Primary Completion Date

January 31, 2013

Study Completion Date

January 31, 2013

Conditions
HyperuricemiaGout
Interventions
DRUG

LC350189

Single Ascending Dose: 10, 25, 50, 100, 200, 400, 600mg Multifle Ascending Dose: 100, 200, 400, 600, 800mg

Trial Locations (1)

110-744

Seoul National University Hospital, Seoul

Sponsors

Lead Sponsor

All Listed Sponsors
lead

LG Life Sciences

INDUSTRY

NCT01361646 - Safety, Tolerability and Pharmacokinetic/Pharmacodynamic Characteristics of LC350189 | Biotech Hunter | Biotech Hunter